Abstract
Objective To investigate the clinical efficacy of ganciclovir (GCV) in the treatment of children with infectious mononucleosis (IM) and to detect the GCV' s influence on EB virus specific antibodies (VCA-IgM).Methods Sixty children with IM was collected from Qingbaijiang people' s hospital from January 2011 to January 2014.The patients were divided into treatment group and control group randomly.Patients in treatment group were given GCV,patients in control group were given IFN-α as treatment.The clinical symptoms improved,treatment efficiency,VCA-IgM and side effect were tested and compared between these two groups.Results The mean antipyretic time and mean term of sore throat relief was 3.57 d ± 1.24 d and 4.76 d ± 1.35 d respectively in treatment group,which were significantly shorter than the time in control 4.73d ± 1.36 d and 6.22d ± 1.75d,respectively.The effective rate of treatment group was significantly higher than that of control group 50.0％ vs 26.7％.Three months after treatment,the positive rate of EBv-VCA-IgM in treatment group was significantly lower than that in control group 13.3％ vs 53.3％.No severe side effect was observed in treatment group.Conclusions GCV is effective in treating children with IM.GCA can decrease EBv-VCA-IgM effectively. Key words: Children with infectious mononucleosis; EB virus ; Ganciclovir
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
